TP53 and cancer: Studying the self-ubiquitination process of Pirh2 at the molecular level opens a new gateway to therapeutic techniques that can focus on counteracting the effects of Pirh2 expression in cancer patients by restoring self-ubiquitination activity and thus releasing p53 continuous inhibition.